INS is Gazyva’s second immune-mediated indication, following an approval last October in adult lupus nephritis, a potentially ...

BioNTech is set to shutter multiple sites in Germany, impacting about 1,800 jobs, after efforts to find buyers fell through.

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...

Eli Lilly’s portfolio of weight loss and diabetes medications have become a dominant force in the market—but access to the ...

The commercial environment facing today's life sciences sales teams looks very different from the one many organizations were ...

AstraZeneca has re-upped its UNICEF-partnered Young Health Programme (YHP), committing to a new five-year phase that will ...

Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...

From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater ...

Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...

Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...

In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...

Par Health has issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection ...